SYT7

SYT7 is a Ca2+-sensing synaptotagmin that mediates short-term presynaptic facilitation by promoting Ca2+-dependent overfilling and refilling of readily releasable vesicle pools [PMID:bio_10.1101_2024.09.10.612312, PMID:bio_10.1101_2024.09.10.612266]. At mossy fiber–CA3 synapses, dentate gyrus-specific Syt7 knockout selectively abolishes short-term facilitation without altering basal release or LTP, and this loss degrades CA3 co-activity and spatial pattern-completion memory in vivo [PMID:bio_10.1101_2024.09.10.612312]; in prefrontal cortical neurons Syt7 knockdown likewise abolishes facilitation by slowing the Ca2+-dependent refilling of high-fusion-probability release sites [PMID:bio_10.1101_2024.09.10.612266]. Alternative splicing of the SYT7 juxtamembrane linker generates isoforms that differ in their biophysical behavior — α and β isoforms undergo liquid–liquid phase separation while the γ isoform aggregates — and these isoforms diverge in their capacity to tune facilitation versus depression, with SYT7 clustering resolved in the active zone by super-resolution imaging [PMID:bio_10.1101_2025.10.27.684894]. The slow-release mechanism depends on C2B–SNARE interactions and C2-domain polybasic motifs, as shown for the C. elegans analog SNT-3 [PMID:bio_10.1101_2025.09.30.679486]. SYT7 expression is set by transcriptional inputs including an OGG1-controlled program in pancreatic β cells, where SYT7 acts downstream of OGG1 to support insulin exocytosis (PMID:37209177), and a G-quadruplex element in its promoter (PMID:39320967). Beyond neurons, SYT7 contributes to vesicular/endo-lysosomal trafficking — it localizes with SYT1 to late endo-lysosomes and MR1 vesicles where its loss impairs MR1 antigen presentation [PMID:bio_10.1101_2025.06.23.660389] — and in cancer it drives exosome secretion and stabilizes partner proteins by limiting their ubiquitination, including BRCA1-dependent HMGB3 stabilization in thyroid cancer (PMID:35073278), SYVN1-substrate KNTC1 in CLL (PMID:37280656), and ALDH1A3 in nasopharyngeal carcinoma (PMID:40346036).

1. 2021 Medium

   Established SYT7 as a transcriptionally regulated downstream effector in epithelial cancer, opening a non-neuronal functional axis.

   Evidence Expression microarray with shRNA double-knockdown rescue in HNSCC cells, in vitro and xenograft

   PMID:34930262

   Open questions at the time

   • Does not define how SYT7 protein executes pro-tumor phenotype downstream
   • Single lab, single tumor type
2. 2022 Medium

   Showed SYT7 stabilizes oncogenic substrates by interfering with ubiquitination, revealing a protein-stability mechanism distinct from its vesicle-fusion role.

   Evidence Co-IP of SYT7–BRCA1, ubiquitination assay, HMGB3 knockdown rescue across cell lines and xenograft (thyroid cancer)

   PMID:35073278

   Open questions at the time

   • Co-IP without structural definition of binding interface
   • Mechanism of ubiquitination inhibition not resolved
3. 2023 Medium

   Extended the ubiquitination-inhibition model to additional E3-ligase/substrate pairs and to exosome-mediated paracrine signaling, generalizing SYT7's oncogenic mechanisms.

   Evidence Co-IP/IP and rescue for KNTC1/SYVN1 (CLL); exosome quantification, syntaxin Western blots, HUVEC co-culture and mTOR analysis (NSCLC)

   PMID:37280656 PMID:37774826

   Open questions at the time

   • Direct enzymatic deubiquitination activity of SYT7 not demonstrated
   • CEP55 exosome transfer mechanism partly inferred
4. 2023 Medium

   Placed SYT7 downstream of OGG1 in controlling regulated exocytosis in a non-cancer secretory context (insulin release).

   Evidence Iron-overload, Ogg1-null and db/db mouse models with SYT7 overexpression rescue and insulin secretion assays

   PMID:37209177

   Open questions at the time

   • Mechanism by which OGG1 drives SYT7 transcription not defined
   • Link to the synaptic facilitation mechanism unexplored
5. 2024 High

   Demonstrated causally that SYT7 mediates short-term presynaptic facilitation via Ca2+-dependent overfilling/refilling of release sites and that this facilitation supports memory.

   Evidence DG-specific conditional KO and L2/3 cortical knockdown with slice electrophysiology, in vivo Ca2+ imaging, and behavioral assays

   PMID:bio_10.1101_2024.09.10.612266 PMID:bio_10.1101_2024.09.10.612312

   Open questions at the time

   • Molecular structure of the overfilling mechanism not resolved
   • Preprint, single-lab readouts
6. 2024 Medium

   Identified a promoter G-quadruplex as a cis-regulatory element controlling SYT7 transcription and a druggable handle for suppressing tumor SYT7 expression.

   Evidence Circular dichroism, G-quadruplex mutagenesis, and TMPyP4/Pyridostatin ligand treatment with expression/proliferation readouts

   PMID:39320967

   Open questions at the time

   • Trans-acting factors binding the G-quadruplex not identified
   • Tissue specificity of regulation unclear
7. 2025 Medium

   Resolved the molecular logic of SYT7 isoform diversity: juxtamembrane-linker splicing switches between phase-separating and aggregating forms that differentially tune facilitation versus depression.

   Evidence Phase-separation assays, iGluSnFR imaging, MINFLUX super-resolution localization of active-zone clusters

   PMID:bio_10.1101_2025.10.27.684894

   Open questions at the time

   • Functional role of condensates in vivo not established
   • Preprint, not independently replicated
8. 2025 Medium

   Defined the C2B–SNARE interface and C2-domain polybasic motifs as the structural basis for slow Ca2+-triggered release, distinguishing SYT7-type from SYT1-type mechanisms.

   Evidence Electrophysiology with targeted SNARE-binding mutagenesis and AlphaFold3 modeling of the C. elegans analog SNT-3

   PMID:bio_10.1101_2025.09.30.679486

   Open questions at the time

   • Findings in C. elegans ortholog, not human SYT7
   • Direct structure of the human C2B–SNARE complex not determined
9. 2025 Medium

   Connected SYT7 loss to disease-relevant synaptic dysfunction (TDP-43 cryptic splicing) and to endo-lysosomal antigen-presentation trafficking, broadening its trafficking roles.

   Evidence TDP-43 knockdown in iPSC neurons with ASO rescue and postmortem validation; SYT7/SYT1 localization and knockdown affecting MR1 vesicles and MAIT activation

   PMID:bio_10.1101_2025.06.23.660389 PMID:bio_10.1101_2025.08.28.672801

   Open questions at the time

   • Whether SYT7 acts as a Ca2+ sensor at MR1 vesicles not tested
   • Preprints, single labs

• How SYT7's vesicle-fusion Ca2+-sensing activity mechanistically relates to its reported protein-stabilization and ubiquitination-inhibition functions in cancer remains unresolved.
• No unifying biochemical model linking synaptic and oncogenic mechanisms
• No direct demonstration that SYT7 possesses or recruits deubiquitinating activity
• Human in vivo structural data on the C2B–SNARE interface lacking